QuidelOrtho (NASDAQ:QDEL) CFO Joseph Busky Purchases 3,370 Shares

QuidelOrtho Corporation (NASDAQ:QDEL) CFO Joseph Busky bought 3,370 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were acquired at an average price of $23.66 per share, for a total transaction of $79,734.20. Following the transaction, the chief financial officer owned 10,290 shares in the company, valued at $243,461.40. This represents a 48.70% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

QuidelOrtho Trading Down 0.7%

Shares of QuidelOrtho stock opened at $23.58 on Friday. The company has a market capitalization of $1.60 billion, a P/E ratio of -1.42 and a beta of 0.68. The stock has a fifty day simple moving average of $29.56 and a 200 day simple moving average of $27.71. QuidelOrtho Corporation has a 12-month low of $19.50 and a 12-month high of $42.50. The company has a current ratio of 1.50, a quick ratio of 0.98 and a debt-to-equity ratio of 1.29.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03. QuidelOrtho had a negative net margin of 41.46% and a positive return on equity of 5.91%. The firm had revenue of $723.60 million for the quarter, compared to the consensus estimate of $699.80 million. During the same period in the previous year, the firm earned $0.63 EPS. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, sell-side analysts anticipate that QuidelOrtho Corporation will post 2.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

QDEL has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 7th. UBS Group set a $30.00 price target on QuidelOrtho in a report on Thursday. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, January 22nd. Finally, Citigroup lifted their target price on QuidelOrtho from $23.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $31.50.

QuidelOrtho News Summary

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: CEO Brian Blaser purchased 10,540 shares (~$23.59 avg), increasing his stake by ~35.7% — a strong insider vote of confidence from the CEO. CEO Form 4
• Positive Sentiment: Director Matthew Strobeck bought 10,000 shares (~$23.96 avg), increasing his stake substantially — another internal signal supporting management’s view of value. Director Form 4
• Positive Sentiment: CFO Joseph Busky also bought 3,370 shares (~$23.66 avg), a meaningful increase in his ownership. Insider buys from multiple officers can signal confidence in longer-term prospects. CFO Form 4
• Neutral Sentiment: Q4 results beat consensus: EPS $0.46 vs. $0.43 and revenue $723.6M vs. $699.8M — top-line strength was driven by Labs and global growth. This is supportive but not enough to offset other headwinds. Zacks: Q4 Earnings Beat
• Neutral Sentiment: Company outlined a 2026 revenue target of $2.7B–$2.9B and emphasized R&D pipeline progress — positive for long-term growth, but investors are focused on near-term profitability and execution. Seeking Alpha: 2026 Revenue Target
• Negative Sentiment: FY2026 guidance came in light: EPS $2.00–$2.42 vs. consensus ~ $2.49 and revenue guidance $2.7B–$2.9B vs. ~$2.8B consensus — the EPS range disappointed investors and likely drove most of the selling pressure. AAII: Why QDEL Is Down
• Negative Sentiment: Margins compressed in Q4 and management cited respiratory weakness weighing on profitability — margin recovery is central to meeting upside expectations and was highlighted in negative market commentary. Yahoo: Q4 Deep Dive
• Negative Sentiment: Planned retirement of the CFO was announced (timing/succession details matter); leadership changes in finance can create near-term uncertainty until a successor is named. TipRanks: CFO Retirement

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC boosted its position in QuidelOrtho by 3,691.7% during the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after acquiring an additional 886 shares in the last quarter. Salomon & Ludwin LLC increased its position in shares of QuidelOrtho by 100.6% during the third quarter. Salomon & Ludwin LLC now owns 989 shares of the company’s stock valued at $30,000 after acquiring an additional 496 shares in the last quarter. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho during the fourth quarter valued at $29,000. Hantz Financial Services Inc. raised its holdings in shares of QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of QuidelOrtho by 2,460.9% during the 2nd quarter. Allworth Financial LP now owns 1,178 shares of the company’s stock valued at $34,000 after buying an additional 1,132 shares during the period. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.